December 1, 2021
PAR-22-036 - Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
National Institute of Mental Health (NIMH)
This notice announces changes to the locus of review of Funding Opportunity Announcement (FOA) PAR-22-036 "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)" and clarifies the Application Types Allowed.
The following sections of PAR-22-036 have been modified to reflect revisions to Locus of Review and Application Types Allowed:
Currently Reads:
Section V. Application Review Information
2. Review and Selection Process
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIMH, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
Modified to Read (changes shown in bold italics):
Section V. Application Review Information
2. Review and Selection Process
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
Currently Reads:
Part 2. Full Text of Announcement
Section II. Award Information
Application Types Allowed:
New
Renewal
Resubmission
Revision
Renewal of RFA-MH-21-105 and PAR-22-035
Resubmission of RFA-MH-21-105 and PAR-22-035
Revision of RFA-MH-21-105 and PAR-22-035
Modified to Read:
Part 2. Full Text of Announcement
Section II. Award Information
Application Types Allowed:
New
Renewal of RFA-MH-21-105 and PAR-22-035
Resubmission of RFA-MH-21-105 and PAR-22-035
Revision of RFA-MH-21-105 and PAR-22-035
All other aspects of this FOA remain unchanged.
Laura M. Rowland, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-480-8335
Email: laura.rowland@nih.gov